CNSBio is a clinical-stage biotechnology company commercialising novel combination therapies for the treatment of pain and other diseases of the nervous system.

The company’s strategy is based on the development and exploitation of innovative methods to treat  disease using combinations of previously approved drugs or clinical-stage pharmaceutical compounds for which there is already strong evidence of safety in humans.